[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350983-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350983-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","modeling-caf-tumor-interactions-to-overcome-therapy-resistance","Modeling CAF-tumor interactions to overcome therapy resistance","","Cancer-associated fibroblasts (CAFs) are a key component of the tumor microenvironment, shaping cancer progression, metastasis, and treatment resistance. This review synthesizes CAF subtypes across cancer types, emphasizing their heterogeneity, plasticity, and distinct phenotypes. Focusing on renal cell carcinoma, it links CAF markers with disease progression and treatment outcomes, supporting CAF-induced drug resistance and counter-strategies. It also details CAF roles in vivo and in vitro, including 2D and 3D co-culture systems that better reproduce tumor microenvironment-driven therapeutic resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/modeling-caf-tumor-interactions-to-overcome-therapy-resistance/350983/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/modeling-caf-tumor-interactions-to-overcome-therapy-resistance/350983.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role do cancer-associated fibroblasts (CAFs) play in cancer progression and therapy resistance?","Question",{"text":63,"@type":64},"CAFs contribute to cancer progression, metastasis, and treatment resistance by promoting tumor proliferation, invasion, and survival. Their activated phenotypes can drive drug resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does this review connect CAF markers to clinical outcomes in renal cell carcinoma?",{"text":68,"@type":64},"It reviews correlations between CAF markers, disease progression, and treatment outcomes in renal cell carcinoma. The findings support CAF-induced drug resistance and highlight potential therapeutic strategies.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are CAF-tumor co-culture models emphasized in overcoming resistance?",{"text":72,"@type":64},"The review explains that integrating CAFs into in vitro co-culture systems, including 2D and 3D models, better recapitulates the tumor microenvironment. These platforms help decipher CAF-tumor crosstalk and reflect CAF-driven therapeutic resistance for improved drug development.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350983,1790921857,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Gubala et al. Journal of Experimental & Clinical Cancer Research (2026) 45:41 [https://doi.org/10.1186/s13046-025-03633-y](https://doi.org/10.1186/s13046-025-03633-y)  \nJournal of Experimental & Clinical Cancer Research  \nREVIEW Open Access  \nModeling CAF-tumor interactions to overcome therapy resistance  \nJakub Gubala 1,2,3, Daniel Benamran4, PetrosTsantoulis5, Valentin Mieville 1,2,3, Massimo Valerio4 and Patrycja Nowak-Sliwinska 1,2,3*  \nAbstract  \nCancer-associated fibroblasts (CAFs) represent an interesting component of the tumor microenvironment, playing a crucial role in cancer progression, metastasis, and treatment resistance. This review provides a comprehensive overview of identified subtypes across various cancer types, highlighting their inter-tumor heterogeneity, plasticity, and function of the different CAF phenotypes. With a focus on renal cell carcinoma, we reviewed the correlations between CAF markers, disease progression, and treatment outcomes. This approach underlined the existence of CAF-induced drug resistance and therapeutic strategies that can be utilized to overcome this extrinsic resistance. A major focus of this review is the role of CAFs in inducing drug resistance, a phenomenon observed in both in vivo and in vitro cancer models. We discuss the integration of CAFs in several in vitro co-culture systems cultivated in two-and three-dimensional models, as well as their contributions to deciphering CAF-tumor crosstalk. These platforms better recapitulate the tumor microenvironment, reflecting CAF-induced therapeutic resistance. Ultimately, this review underlines the crucial role of CAF-incorporated co-culture systems in advancing drug development, especially in the context of tissue-and subtype-specific CAF targeting.  \nKeywords Cancer-associated fibroblasts, Clear cell renal cell carcinoma, Combined treatment, The extracellular matrix, Tumor microenvironment  \n*Correspondence:  \nPatrycja Nowak-Sliwinska  \n[Patrycja.Nowak-Sliwinska@unige.ch](Patrycja.Nowak-Sliwinska@unige.ch)  \n1Cancer Systems Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Geneva 1211, Switzerland  \n2Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva 1211, Switzerland  \n3Translational Research Center in Oncohaematology, Geneva  \n1211, Switzerland  \n4Division of Urology, Geneva University Hospitals, Geneva, Switzerland 5Department of Oncology, Geneva University Hospitals, Geneva, Switzerland  \nIntroduction  \nCancer prevails as the leading cause of death worldwide. Despite recent advancements in therapeutic strategies, an unmet need for new approaches remains. Frequently, research focuses mostly on cancer cells, overlooking the intricate dynamics of the tumor microenvironment (TME). TME contains various cell types, including fibroblasts, immune cells, pericytes, and endothelial cells (ECs), as well as extracellular matrix (ECM) and signaling molecules. Constant communication between TME and cancer cells can contribute to increased tumor proliferation and invasion, drug resistance, inflammation, cancer cell survival, or immune evasion. Cells within TME are often also described as being responsible for increasing the tumor heterogeneity [1]. Pre-clinical models frequently lack the architectural complexity of the tumor  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted","cbCaieRllxPeccJp","https://ap.wps.com/l/cbCaieRllxPeccJp","pdf",6018425,26,"English","# Abstract\n## Introduction","[{\"question\":\"What role do cancer-associated fibroblasts (CAFs) play in cancer progression and therapy resistance?\",\"answer\":\"CAFs contribute to cancer progression, metastasis, and treatment resistance by promoting tumor proliferation, invasion, and survival. Their activated phenotypes can drive drug resistance.\"},{\"question\":\"How does this review connect CAF markers to clinical outcomes in renal cell carcinoma?\",\"answer\":\"It reviews correlations between CAF markers, disease progression, and treatment outcomes in renal cell carcinoma. The findings support CAF-induced drug resistance and highlight potential therapeutic strategies.\"},{\"question\":\"Why are CAF-tumor co-culture models emphasized in overcoming resistance?\",\"answer\":\"The review explains that integrating CAFs into in vitro co-culture systems, including 2D and 3D models, better recapitulates the tumor microenvironment. These platforms help decipher CAF-tumor crosstalk and reflect CAF-driven therapeutic resistance for improved drug development.\"}]","Modeling CAF-tumor interactions to overcome therapy resistance | PDF",1790092196,66,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3803478546c510dc38ba2a422dd9390f.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95d5ba10d1e26c595416d7a75f578dce.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62077491133609170a0eaf9fd85060b2.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/acdb9febcb3162c7bbe75898a414be76.webp",980,1306]